This clinical trial is focused on studying a condition known as metastatic castration-resistant prostate cancer (mCRPC). This is a type of prostate cancer that continues to grow and spread even when the amount of male hormones in the body is reduced to very low levels. The study is comparing a new treatment called MK-5684 with two existing medications, abiraterone acetate and enzalutamide, which are already used to treat this type of cancer. The purpose of the study is to see how well MK-5684 works compared to the other two medications in terms of helping patients live longer and slowing down the progression of the cancer.

Participants in the study will receive either MK-5684 or one of the approved medications, abiraterone acetate or enzalutamide. The study will monitor the participants over a period to assess their overall survival and the progression of their cancer. The study will also look at other factors such as the time it takes for the cancer to progress, the response to the treatment, and any side effects experienced by the participants. The study aims to provide valuable information on the effectiveness and safety of MK-5684 as a potential treatment option for patients with mCRPC.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to gather data on the treatment’s impact. The study will help determine if MK-5684 can offer a new and effective treatment option for those with advanced prostate cancer who have already undergone hormonal therapy and chemotherapy. This research is important for advancing the understanding and treatment of metastatic castration-resistant prostate cancer.